Pharsight

Precedex patents expiration

PRECEDEX's oppositions filed in EPO
PRECEDEX Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338470 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8455527 HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8648106 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US9616049 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8242158 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US10016396 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US9320712 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US9616049

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US8648106

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US8242158

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US8455527

(Pediatric)

HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US9320712

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US8338470

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

Precedex is owned by Hospira.

Precedex contains Dexmedetomidine Hydrochloride.

Precedex has a total of 13 drug patents out of which 0 drug patents have expired.

Precedex was authorised for market use on 17 December, 1999.

Precedex is available in injectable;injection dosage forms.

Precedex can be used as use for sedation.

The generics of Precedex are possible to be released after 04 July, 2032.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Dec 16, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 December, 1999

Treatment: Use for sedation

Dosage: INJECTABLE;INJECTION

How can I launch a generic of PRECEDEX before it's drug patent expiration?
More Information on Dosage

PRECEDEX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic